Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RARE vs VERA, IRON, QURE: Days Payable Comparison
For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ultragenyx Pharmaceutical Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Days Payable distribution charts can be found below:
* The bar in red indicates where Ultragenyx Pharmaceutical's Days Payable falls into.
Ultragenyx Pharmaceutical Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ultragenyx Pharmaceutical's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ultragenyx Pharmaceutical (MEX:RARE) has a Days Payable of 110.95 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ultragenyx Pharmaceutical and its competitors. This is 72% below median its historical median of 389.31. Over the past decade, Ultragenyx Pharmaceutical's Days Payable has ranged from 117.20 to 2,600,625.00. According to the industry distribution chart, Ultragenyx Pharmaceutical ranks #322 out of 701 companies in the Biotechnology industry, placing it in the top 45.9%.
Is Ultragenyx Pharmaceutical's Days Payable too high?
Ultragenyx Pharmaceutical's current Days Payable of 110.95 is 72% below median its 10-year median of 389.31. Over the past 10 years, this metric has ranged from a low of 117.20 to a high of 2,600,625.00. The Biotechnology industry median Days Payable is 112.84. Ultragenyx Pharmaceutical's value of 110.95 is 1.7% below this industry median. Based on the distribution chart, Ultragenyx Pharmaceutical ranks #322 out of 701 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's Days Payable compare to VERA and IRON?
According to the Biotechnology industry distribution chart, Ultragenyx Pharmaceutical ranks #322 out of 701 companies for Days Payable. This puts Ultragenyx Pharmaceutical in the upper half of its industry. The industry median Days Payable is 112.84. Ultragenyx Pharmaceutical's value of 110.95 is 1.7% below this benchmark. Historically, Ultragenyx Pharmaceutical's own Days Payable has ranged from 117.20 to 2,600,625.00 over the past decade. While the company's 10-year median is 389.31 vs. the industry median of 112.84, Ultragenyx Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ultragenyx Pharmaceutical's current Days Payable of 110.95 is 1.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ultragenyx Pharmaceutical and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ultragenyx Pharmaceutical's current Days Payable is 110.95, which is 72% below median its own 10-year median of 389.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Ultragenyx Pharmaceutical (MEX:RARE) has a current Days Payable of 110.95. The stock's GF Value™ is MXN1,699.44, compared to a current price of MXN1,150.56 — trading 32.3% below its estimated fair value. The current Days Payable is 110.95, which is 72% below median its 10-year median of 389.31 and 1.7% below the Biotechnology industry median of 112.84. Ultragenyx Pharmaceutical's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (MEX:RARE), the current Days Payable is 110.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ultragenyx Pharmaceutical (MEX:RARE) Overvalued in 2026?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued.
The current stock price of MXN1,150.56 is trading 32.3% below its estimated GF Value™ of MXN1,699.44.
Key valuation signals for MEX:RARE:
Days Payable: 110.95 (72% below median its 10-year median of 389.31)
GF Value™: MXN1,699.44 vs. price of MXN1,150.56 (32.3% below fair value)
Industry Position: 1.7% below the Biotechnology median (#322 of 701)
No single metric tells the full story. See the MEX:RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
66GF Score
Get the complete analysis for MEX:RARE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RARE has been successfully added to your 
